Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action

Abstract

Ibrexafungerp and fosmanogepix have novel mechanisms of action and will provide effective options for the treatment of <i>Candida</i> infections (including those caused by multiresistant <i>Candida</i> spp). Rezafungin, an echinocandin with an extended half-life allowing for once weekly administration, will be particularly valuable for outpatient treatment and prophylaxis. Despite this, there is an urgent need to garner clinical data on investigational drugs, especially in the current rise of azole-resistant and multidrug-resistant <i>Candida</i> spp.